Content and data provided by various third parties and Fidelity − Terms of Use | Help/Glossary
Research > ETFs > ETF / ETP Commentary > 

How Tempus AI Built a Defensible Data Moat in Precision Healthcare

BY | ETF Database
7:40 am ET 10/22/26 | 14 VIEWS
As access to powerful general-purpose AI models expands, access alone offers limited differentiation. In precision healthcare, competitive advantage can come from combining proprietary clinical data, specialized models, and integration into diagnostic workflows.According to a recent McKinsey & Company report, the true competitive moat could be found around securing proprietary data and embedding your software deeply into daily workflows. Tempus AI is a perfect example of this in action.Key Takeaways Pure software companies face systemic access bottlenecks due to strict regulations and proprietary clinical data silos. Tempus AI (TEM) sits at the intersection of AI infrastructure and clinical diagnostics, leveraging a vast proprietary multimodal database. The company is a holding in both the ROBO Global Artificial Intelligence ETF (THNQ B-) and the ROBO Global Healthcare Technology and Innovation ETF (HTEC B). The AI Data Moat BottleneckPhysical laboratory hardware creates a major bottleneck in AI-driven drug discovery. However, a second constraint lies ahead: Secure access to proprietary patient data. Compute alone cannot solve the challenge of obtaining, connecting, and maintaining usable clinical data. Doing so requires healthcare relationships, appropriate data rights, and substantial integration and curation. Tempus AI (TEM) is an example of this integrated approach.Why Static Datasets Aren't EnoughTempus combines clinical laboratory operations with healthcare-provider integrations to assemble and curate multimodal datasets, including de-identified clinical and genomic records. Connecting clinical history with molecular testing can help contextualize diagnostic findings and improve patient care. Tempus designed its business around integrated data pipelines with healthcare partners from the beginning. While anyone with enough capital can buy a static dataset once, setting up live, compliant systems that pull updated clinical data continuously creates a moat that any single company would struggle to replicate. This setup mirrors two key moats outlined by McKinsey: Privileged data and deep workflow embeddedness. Deep integrations can create switching costs through the work required to rebuild data connections and clinical workflows.Bridging Tech Infrastructure & Precision HealthcareBecause Tempus combines tech infrastructure with clinical execution, it plays a dual role across thematic strategies. The stock has emerged as a top holding in the ROBO Global Artificial Intelligence ETF (THNQ B-), sitting alongside cloud infrastructure giants and chipmakers. At the same time, its clinical decision-support tools and diagnostic research make it a natural fit in the ROBO Global Healthcare Technology and Innovation ETF (HTEC B). Read more: THNQ Hits Milestone Highs on Record Outperformance Over QQQ Looking for regular updates? Subscribe here for weekly insights on robotics, AI, and healthcare technology, delivered straight to your inbox. For more news, information, and analysis, visit the Artificial Intelligence Content Hub. vettafi.com is owned by VettaFi LLC (“VettaFi”). VettaFi is the index provider for HTEC and THNQ, for which it receives an index licensing fee. However, HTEC and THNQ are not issued, sponsored, endorsed, or sold by VettaFi. VettaFi and its affiliates have no obligation or liability in connection with the issuance, administration, marketing, or trading of HTEC and THNQ.

More Commentary

Navigate Large-Cap Growth Risk With Insider Value Investing
BY | ETF Database
8:24 am ET 10/22/26 | 16 VIEWS
MANGOS ETFs: The Fruits of AI Innovation
BY | ETF Database
5:19 am ET 10/22/26 | 23 VIEWS
Buy on the Dip Prospects: October 21 Edition
BY | ETF Database
7:46 am ET 10/22/26 | 18 VIEWS
View more Commentary

Search Commentary

Enter Keyword(s)
Filter Results

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.